BMRN - BioMarin Pharmaceutical Non-GAAP EPS of $0.54 beats by $0.07 revenue of $595.3M in-line
2023-07-31 16:06:54 ET
- BioMarin Pharmaceutical press release ( NASDAQ: BMRN ): Q2 Non-GAAP EPS of $0.54 beats by $0.07 .
- Revenue of $595.3M (+11.5% Y/Y) in-line.
- FY23 Total Revenues Guidance unchanged at $2,375M to $2,500M, vs. consensus of $2.44B.
- Non-GAAP Diluted EPS Guidance changed to $1.80 to $2.05, vs. consensus of $2.10, from $1.85 to $2.10.
For further details see:
BioMarin Pharmaceutical Non-GAAP EPS of $0.54 beats by $0.07, revenue of $595.3M in-line